Beneficial effects of inhaled surfactant in patients with COVID-19-associated acute respiratory distress syndrome - 18/08/21
![](/templates/common/images/mail.png)
Abstract |
Background |
We have investigated the use of nebulized surfactant as a potential therapeutic option for the patients with coronavirus disease 2019 (COVID-19)-associated acute respiratory distress syndrome (ARDS) undergoing non-invasive ventilation.
Methods |
The patients were divided into 2 groups: surfactant (n = 33) and control (n = 32). The subjects in the surfactant group received the inhaled surfactant at daily dose of 150–300 mg. The oxygenation parameters and several clinical outcomes were analyzed.
Results |
On the 5 day of therapy, PaO2/FiO2 improved significantly in the surfactant group compared to the control group (184 (155–212) mmHg vs 150 (91–173) mmHg, p = 0.02). The inhaled surfactant significantly reduced the need for transfer of patients to intensive care units (24.2% vs 46.9%, p = 0.05) and invasive mechanical ventilation (18.2% vs 40.6%, p = 0.04). Even more, the nebulized surfactant shortened the length of non-invasive ventilation (7 (3–13) days vs 11 (5–22) days, p = 0.02) and time spent in hospital (18 (16–27) days vs 26 (21–31) days, p = 0.003) in patients suffering from COVID-19-linked ARDS.
Conclusions |
Our preliminary data provided indications that inhaled surfactant therapy may represent a promising option for patients with COVID-19-associated ARDS. However, larger clinical trials are crucially needed.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Effects of nebulized surfactant were investigated in COVID-19 and ARDS patients. |
• | The application of inhaled surfactant improved the oxygenation parameters. |
• | It also had beneficial effects with regard to several clinical outcomes. |
• | Our data indicated that inhaled surfactant may be the promising therapeutic option. |
Keywords : Inhalation, Surfactant, COVID-19, Acute respiratory distress syndrome
Plan
Vol 185
Article 106489- août 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.